CRIS Current Research Information System

GELSOMINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.757
EU - Europa 1.017
NA - Nord America 793
AF - Africa 117
SA - Sud America 72
OC - Oceania 4
Totale 3.760
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 774
CN - Cina 528
IT - Italia 519
SG - Singapore 499
VN - Vietnam 350
HK - Hong Kong 146
NL - Olanda 93
IN - India 83
DE - Germania 79
KR - Corea 77
SE - Svezia 53
CI - Costa d'Avorio 48
IE - Irlanda 48
GB - Regno Unito 45
BR - Brasile 43
FI - Finlandia 41
CH - Svizzera 35
FR - Francia 35
TG - Togo 28
JP - Giappone 24
RU - Federazione Russa 22
JO - Giordania 20
SC - Seychelles 16
CA - Canada 15
BG - Bulgaria 14
NG - Nigeria 13
ID - Indonesia 11
AR - Argentina 10
AT - Austria 10
ES - Italia 7
ZA - Sudafrica 7
EC - Ecuador 6
AU - Australia 4
BE - Belgio 4
CL - Cile 4
LT - Lituania 4
MX - Messico 4
PK - Pakistan 4
PL - Polonia 4
IQ - Iraq 3
MA - Marocco 3
TR - Turchia 3
VE - Venezuela 3
BD - Bangladesh 2
CO - Colombia 2
KZ - Kazakistan 2
PY - Paraguay 2
TW - Taiwan 2
EE - Estonia 1
ET - Etiopia 1
GM - Gambi 1
GR - Grecia 1
KG - Kirghizistan 1
LB - Libano 1
LI - Liechtenstein 1
PE - Perù 1
SR - Suriname 1
TH - Thailandia 1
UA - Ucraina 1
Totale 3.760
Salva come PNG Salva come JPEG
Città #
Singapore 340
Hefei 195
Ashburn 176
Hong Kong 142
Ho Chi Minh City 113
Bologna 111
Seoul 77
Hanoi 73
Beijing 68
Santa Clara 65
Abidjan 48
Dublin 48
Milan 48
Dallas 42
Chandler 38
Boardman 37
Lomé 28
Bern 27
Los Angeles 25
Vicenza 24
Munich 23
Cinquefrondi 22
Helsinki 21
Turin 21
Amman 20
New York 20
Visakhapatnam 19
Bengaluru 17
Messina 16
Hyderabad 15
Tokyo 15
Rome 14
Sofia 14
Turku 14
Abeokuta 13
Redondo Beach 13
Southend 13
Fairfield 12
Princeton 12
Seattle 12
Da Nang 11
Biên Hòa 10
Houston 10
The Dalles 10
Buffalo 9
Frankfurt am Main 9
Haiphong 9
London 9
Modena 9
Quận Bình Thạnh 9
Shanghai 9
Bắc Ninh 8
Ferrara 8
Guangzhou 8
Jakarta 8
Paris 8
Phoenix 8
Tongling 8
Vinh 8
Amsterdam 7
Boydton 7
Bắc Giang 7
Cesena 7
Chicago 7
Vũng Tàu 7
Ha Long 6
Ninh Bình 6
Redmond 6
Toronto 6
Berlin 5
Falkenstein 5
Guayaquil 5
Lappeenranta 5
Naples 5
Phủ Lý 5
Poplar 5
Quận Một 5
Ravenna 5
Rimini 5
Tianjin 5
Vienna 5
Wilmington 5
Boston 4
Brussels 4
Can Tho 4
Johannesburg 4
Montreal 4
Padua 4
Palermo 4
Quận Phú Nhuận 4
Rancho Palos Verdes 4
Seville 4
Shijiazhuang 4
Stockholm 4
São Paulo 4
Thanh Hóa 4
Atlanta 3
Bergamo 3
Bühl 3
Castenaso 3
Totale 2.418
Salva come PNG Salva come JPEG
Nome #
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 241
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 213
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 201
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 192
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 173
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 169
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches 158
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 153
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 138
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 135
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 126
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 118
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 117
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 113
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 113
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer 99
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 91
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 90
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 89
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 88
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 79
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 77
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 76
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 73
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 72
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 69
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 67
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 64
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 63
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management 58
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 57
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors 49
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY 49
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 48
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 48
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 46
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 37
Totale 3.849
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.023
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.023
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 10 2 15 3 2 0 54 8 8 58 26
2022/2023530 14 39 19 19 89 41 45 37 110 23 29 65
2023/2024255 17 16 11 23 19 52 9 31 6 36 31 4
2024/20251.225 54 77 84 92 131 75 136 58 33 113 128 244
2025/20261.653 409 440 232 234 235 103 0 0 0 0 0 0
Totale 3.849